Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00280852
Other study ID # 18940
Secondary ID
Status Completed
Phase N/A
First received January 20, 2006
Last updated November 18, 2011
Start date January 2006
Est. completion date June 2006

Study information

Verified date July 2011
Source AHS Cancer Control Alberta
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Observational

Clinical Trial Summary

To describe the outcome of patients with anaplastic thyroid cancer treated with hyperfractionated radiotherapy and concomitant chemotherapy


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date June 2006
Est. primary completion date June 2006
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- anaplastic thyroid cancer treated with multimodality treatment

Exclusion Criteria:

- differentiated thyroid cancer

Study Design

Time Perspective: Retrospective


Locations

Country Name City State
Canada Tom Baker Cancer Centre Calgary Alberta

Sponsors (1)

Lead Sponsor Collaborator
Alberta Health Services

Country where clinical trial is conducted

Canada, 

See also
  Status Clinical Trial Phase
Recruiting NCT04420754 - Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer Phase 1
Completed NCT02152137 - Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Active, not recruiting NCT04552769 - Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Active, not recruiting NCT04400474 - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Phase 2
Completed NCT02688608 - Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Terminated NCT00095693 - Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Phase 2
Active, not recruiting NCT01240590 - A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Phase 1/Phase 2
Not yet recruiting NCT05819593 - Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Active, not recruiting NCT04579757 - Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06362694 - Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy Phase 2
Recruiting NCT06374602 - Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer Phase 2
Withdrawn NCT01701349 - Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Phase 3
Active, not recruiting NCT03085056 - Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Early Phase 1
Recruiting NCT01774279 - interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Terminated NCT00126568 - Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Completed NCT02244463 - A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer Phase 1/Phase 2
Active, not recruiting NCT05696548 - Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) Phase 2
Terminated NCT00603941 - A Phase 1/2 Study of CS7017, an Oral PPARĪ³ Agonist, in Combination With Paclitaxel Phase 1/Phase 2
Recruiting NCT04238624 - Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer Phase 2
Recruiting NCT06079333 - NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) Phase 2